Results from a comparative pharmacodynamics study have shown the potential benefits of Tresiba (insulin degludec) over a rival in patients with type 1 diabetes.
Danish diabetes giant Novo Nordisk (NOV: N), which gained US approval to sell Tresiba in September 2015, presented the results at the 16th Annual Diabetes Technology Meeting in Bethesda, USA.
Tresiba (0.4 U/kg) was compared with insulin glargine U300 and resulted in lower day-to-day and within-day variability in glucose-lowering effect than its competitor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze